175+ emerging biotechs now accelerating drug development with Veeva Basics

More than 175 emerging biotechs have now standardized on Veeva Basics to establish a technology foundation for speed and growth. 

By bringing clinical, regulatory, quality, medical, and commercial applications into a unified platform, biotechs have the systems they need to scale from startup to commercialization.

Biotechs are using Veeva Basics to build strong internal foundations at every stage. For instance, with Veeva Submissions Publishing Basics, teams gain the capabilities to bring publishing in-house on their own terms. This not only helps them hit critical milestones with greater agility, but also gives them full transparency and control ahead of their first FDA or EMA submissions. 

With pre-configured and pre-validated applications and global support tailored for biotechs, Veeva Basics is far from basic. Read the full press release here.  

As a Public Benefit Corporation (PBC), Veeva is legally committed to being a long-term strategic technology partner to life sciences. Our PBC purpose ensures we remain aligned with the industry’s broader mission to improve health and extend life. 

If you’d like to learn more about how Veeva Basics can support your team, we’d love to speak with members of the BIA community. Feel free to connect, reach out directly, or drop a comment to exchange ideas.